Kathleen Ford Sells 1,813 Shares of Kura Oncology (NASDAQ:KURA) Stock

Kura Oncology, Inc. (NASDAQ:KURA) COO Kathleen Ford sold 1,813 shares of the firm’s stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total value of $15,337.98. Following the completion of the transaction, the chief operating officer owned 153,560 shares of the company’s stock, valued at approximately $1,299,117.60. This represents a 1.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kathleen Ford also recently made the following trade(s):

• On Friday, November 14th, Kathleen Ford sold 6,902 shares of Kura Oncology stock. The shares were sold at an average price of $11.18, for a total value of $77,164.36.

Kura Oncology Stock Down 1.2%

KURA traded down $0.10 during trading on Tuesday, reaching $8.47. 1,149,028 shares of the stock were exchanged, compared to its average volume of 1,287,347. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.12 and a current ratio of 5.12. The stock’s 50 day moving average price is $10.33 and its two-hundred day moving average price is $9.05. Kura Oncology, Inc. has a twelve month low of $5.41 and a twelve month high of $12.49. The stock has a market cap of $737.06 million, a P/E ratio of -3.42 and a beta of 0.25.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). The firm had revenue of $20.75 million during the quarter, compared to the consensus estimate of $17.48 million. Kura Oncology had a negative net margin of 208.48% and a negative return on equity of 65.42%. Equities analysts expect that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on the company. UBS Group upped their price objective on Kura Oncology from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Friday, November 14th. Barclays restated an “overweight” rating and issued a $28.00 price target (up previously from $11.00) on shares of Kura Oncology in a research note on Monday, November 24th. Zacks Research cut shares of Kura Oncology from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kura Oncology in a research report on Thursday, January 22nd. Finally, JMP Securities restated a “market outperform” rating and set a $24.00 target price on shares of Kura Oncology in a research note on Monday, October 20th. Nine equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Kura Oncology currently has an average rating of “Moderate Buy” and an average price target of $28.00.

Institutional Investors Weigh In On Kura Oncology

Institutional investors have recently modified their holdings of the business. EcoR1 Capital LLC raised its holdings in Kura Oncology by 59.1% in the 2nd quarter. EcoR1 Capital LLC now owns 4,200,000 shares of the company’s stock valued at $24,234,000 after acquiring an additional 1,559,702 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its position in shares of Kura Oncology by 101.6% in the third quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company’s stock worth $19,688,000 after purchasing an additional 1,121,228 shares during the period. Qube Research & Technologies Ltd raised its stake in Kura Oncology by 63.0% in the second quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company’s stock valued at $11,032,000 after purchasing an additional 738,761 shares in the last quarter. Acadian Asset Management LLC raised its stake in Kura Oncology by 163.6% in the second quarter. Acadian Asset Management LLC now owns 870,903 shares of the company’s stock valued at $5,022,000 after purchasing an additional 540,482 shares in the last quarter. Finally, Sector Gamma AS bought a new stake in Kura Oncology during the third quarter worth about $3,880,000.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.